Jonas Sundermeyer

Jonas Sundermeyer

Auto-generated profile, based on publicly available information

Jonas Sundermeyer

University Heart and Vascular Center Hamburg, University Medical Center Hamburg‐Eppendorf

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in JACC: Heart Failure
Verified
Journal Article
Closed access
BSBenedikt Schrage
Benedikt Schrage
JSJonas Sundermeyer
Jonas Sundermeyer
SBStefan Blankenberg
Stefan Blankenberg
PCPascal Colson
Pascal Colson
DEDennis Eckner
Dennis Eckner
DWDirk Westermann
Dirk Westermann

26 February 2023 in European Journal of Heart Failure
Verified
Journal Article
Open access
BSBenedikt Schrage
Benedikt Schrage
JSJonas Sundermeyer
Jonas Sundermeyer
BBBenedikt Norbert Beer
Benedikt Norbert Beer
LBLetizia Bertoldi
Letizia Bertoldi
ABAlexander Bernhardt
Alexander Bernhardt
DWDirk Westermann
Dirk Westermann
Aims: Despite its high incidence and mortality risk, there is no evidence-based treatment for non-ischaemic cardiogenic shock (CS). The aim of this study was to evaluate the use of mechanical circulatory support (MCS) for non-ischaemic CS treatment. Methods and results: In this multicentre, international, retrospective study, data from 890 patients with non-ischaemic CS, defined as CS due to severe de-novo or acute-on-chronic heart failure with no need for urgent revascularization, treated with or without active MCS, were collected. The association between active MCS use and the primary endpoint of 30-day mortality was assessed in a 1:1 propensity-matched cohort. MCS was used in 386 (43%) patients. Patients treated with MCS presented with more severe CS (37% vs. 23% deteriorating CS, 30% vs. 25% in extremis CS) and had a lower left ventricular ejection fraction at baseline (21% vs. 25%). After matching, 267 patients treated with MCS were compared with 267 patients treated without MCS. In the matched cohort, MCS use was associated with a lower 30-day mortality (hazard ratio 0.76, 95% confidence interval 0.59–0.97). This finding was consistent through all tested subgroups except when CS severity was considered, indicating risk reduction especially in patients with deteriorating CS. However, complications occurred more frequently in patients with MCS; e.g. severe bleeding (16.5% vs. 6.4%) and access-site related ischaemia (6.7% vs. 0%). Conclusion: In patients with non-ischaemic CS, MCS use was associated with lower 30-day mortality as compared to medical therapy only, but also with more complications. Randomized trials are needed to validate these findings.

23 November 2023 in European Journal of Heart Failure
Verified
Journal Article
Open access
JSJonas Sundermeyer
Jonas Sundermeyer
CKCaroline Kellner
Caroline Kellner
BBBenedikt N. Beer
Benedikt N. Beer
LBLisa Besch
Lisa Besch
ADAngela Dettling
Angela Dettling
BSBenedikt Schrage
Benedikt Schrage
Aims: Heart failure-related cardiogenic shock (HF-CS) accounts for a significant proportion of CS cases. Whether patients with de novo HF and those with acute-on-chronic HF in CS differ in clinical characteristics and outcome remains unclear. The aim of this study was to evaluate differences in clinical presentation and mortality between patients with de novo and acute-on-chronic HF-CS. Methods and results: In this international observational study, patients with HF-CS from 16 tertiary care centres in five countries were enrolled between 2010 and 2021. To investigate differences in clinical presentation and 30-day mortality, adjusted logistic/Cox regression models were fitted. Patients (n = 1030) with HF-CS were analysed, of whom 486 (47.2%) presented with de novo HF-CS and 544 (52.8%) with acute-on-chronic HF-CS. Traditional markers of CS severity (e.g. blood pressure, heart rate and lactate) as well as use of treatments were comparable between groups. However, patients with acute-on-chronic HF-CS were more likely to have a higher CS severity and also a higher mortality risk, after adjusting for relevant confounders (de novo HF 45.5%, acute-on-chronic HF 55.9%, adjusted hazard ratio 1.38, 95% confidence interval 1.10–1.72, p = 0.005). Conclusion: In this large HF-CS cohort, acute-on-chronic HF-CS was associated with more severe CS and higher mortality risk compared to de novo HF-CS, although traditional markers of CS severity and use of treatments were comparable. These findings highlight the vast heterogeneity of patients with HF-CS, emphasize that HF chronicity is a relevant disease modifier in CS, and indicate that future clinical trials should account for this.

28 May 2025 in European Journal of Heart Failure
Verified
Journal Article
Open access
JSJonas Sundermeyer
Jonas Sundermeyer
CKCaroline Kellner
Caroline Kellner
BBBenedikt N. Beer
Benedikt N. Beer
LBLisa Besch
Lisa Besch
ADAngela Dettling
Angela Dettling
BSBenedikt Schrage
Benedikt Schrage
Aims: Heart failure–related cardiogenic shock (HF-CS) accounts for about half of CS cases, with a paucity of data regarding the role of kidney injury in this subset. This study aims to evaluate patient characteristics and outcome associated with renal function in patients with HF-CS. Methods and results: In this multicentre, international, retrospective study, patients with HF-CS from 16 tertiary care centres in five countries were enrolled between 2010 and 2021. To investigate differences in clinical presentation, complications, and 30-day mortality, based on renal function, adjusted logistic and Cox regression models were fitted. Among 1010 HF-CS patients, the median age was 64 (interquartile range [IQR] 52–75) years, with 71.7% being male. Median baseline creatinine was 1.7 (IQR 1.2–2.5) mg/dl, corresponding to an estimated glomerular filtration rate (eGFR) of 41.0 (IQR 25.2–62.2) ml/min/1.73 m2. In patients with acute kidney injury (AKI), 30-day mortality increased with AKI stages (no AKI 41.7%, AKI stage 1 43.3%, AKI stage 2 50.0%, AKI stage 3 63.7%; adjusted hazard ratio [HR] for AKI stage 3 1.97, 95% confidence interval [CI] 1.56–2.48, p < 0.001). Similarly, severe renal dysfunction (eGFR ≤ median) was associated with a 21% higher 30-day mortality risk (61.0% vs. 40.1%; adjusted HR 1.48, 95% CI 1.20–1.84, p < 0.001). Sepsis and bleeding were associated with both AKI and renal dysfunction, even after adjustment. Conclusions: In HF-CS, kidney injury is associated with higher 30-day mortality, potentially mediated by bleeding and sepsis. These findings support the consideration of kidney function as a prognostic marker and call for the development and evaluation of kidney-restoring adjunct interventions in HF-CS.

24 October 2024 in European Journal of Heart Failure
Verified
Journal Article
Open access
JSJonas Sundermeyer
Jonas Sundermeyer
CKCaroline Kellner
Caroline Kellner
BBBenedikt N. Beer
Benedikt N. Beer
ADAngela Dettling
Angela Dettling
LBLisa Besch
Lisa Besch
BSBenedikt Schrage
Benedikt Schrage
Aims: The optimal timing for implementing mechanical circulatory support (MCS) in cardiogenic shock (CS) remains indeterminate. This study aims to evaluate patient characteristics and outcome associated with the time interval between CS onset and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) implementation. Methods and results: In this study, patients with CS treated with MCS at 15 tertiary care centres in three countries were enrolled. Patients treated with MCS were stratified into early (<2 h), intermediate (2–12 h) and delayed (≥12–24 h) MCS implantation by using the time interval between CS onset and MCS device implementation. Adjusted logistic and Cox regression models were fitted to assess the association between timing of MCS implementation, patient characteristics and 30-day mortality. A total of 330 patients with CS treated with VA-ECMO and/or microaxial flow pump were included in this study; 20.9% received early, 55.8% intermediate, and 23.3% delayed MCS. Although crude 30-day mortality was slightly lower in patients with early MCS (58.1% vs. 64.7% vs. 64.3%), adjusted analyses showed no significant association between timing of MCS implantation and 30-day all-cause mortality (hazard ratio [HR] for early vs. intermediate MCS: 0.93, 95% confidence interval [CI] 0.59–1.46, p = 0.74; HR for early vs. delayed MCS: 1.29, 95% CI 0.78–2.13, p = 0.33). Moreover, the incidence of complications, related and unrelated to MCS, did not differ significantly among groups. Conclusion: In this exploratory study of patients with CS treated with MCS, the timing of device implantation within 24 h after CS onset was not associated with mortality. This supports a restrictive MCS approach, reserving its application for patients experiencing CS deterioration despite conventional therapy.

1 March 2023 in JACC: Heart Failure
Verified
Journal Article
Closed access
JSJonas Sundermeyer
Jonas Sundermeyer
SDSalim Dabboura
Salim Dabboura
JWJessica Weimann
Jessica Weimann
BBBenedikt N. Beer
Benedikt N. Beer
PBPeter Moritz Becher
Peter Moritz Becher
BSBenedikt Schrage
Benedikt Schrage